ISIN | LU2226245095 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | Galileo – Biotech Innovation Fund S USD |
Fund Provider |
IPConcept (Luxemburg) S.A.
Zürich, Switzerland Phone: +352 260248-1 E-Mail: info.lu@ipconcept.com Web: www.ipconcept.com |
Fund Provider | IPConcept (Luxemburg) S.A. |
Representative in Switzerland |
IPConcept (Schweiz) AG Zürich Phone: +41 044 224 32 09 |
Distributor(s) | Bellecapital AG |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark. |
Peculiarities |
Current Price * | 57.05 USD | 12.11.2024 |
---|---|---|
Previous Price * | 56.37 USD | 11.11.2024 |
52 Week High * | 74.69 USD | 28.02.2024 |
52 Week Low * | 44.72 USD | 14.11.2023 |
NAV * | 57.05 USD | 12.11.2024 |
Issue Price * | 57.05 USD | 12.11.2024 |
Redemption Price * | 57.05 USD | 12.11.2024 |
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 36,933,868 | |
Unit/Share Assets *** | 821,508 | |
Trading Information SIX |
YTD Performance | -5.25% |
29.12.2023 - 12.11.2024
29.12.2023 12.11.2024 |
---|---|---|
YTD Performance (in CHF) | -0.88% |
29.12.2023 - 12.11.2024
29.12.2023 12.11.2024 |
1 month | +5.92% |
14.10.2024 - 12.11.2024
14.10.2024 12.11.2024 |
3 months | +6.96% |
12.08.2024 - 12.11.2024
12.08.2024 12.11.2024 |
6 months | -1.74% |
13.05.2024 - 12.11.2024
13.05.2024 12.11.2024 |
1 year | +25.72% |
13.11.2023 - 12.11.2024
13.11.2023 12.11.2024 |
2 years | -20.53% |
14.11.2022 - 12.11.2024
14.11.2022 12.11.2024 |
3 years | -57.68% |
12.11.2021 - 12.11.2024
12.11.2021 12.11.2024 |
5 years | -61.97% |
31.03.2021 - 12.11.2024
31.03.2021 12.11.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Krystal Biotech Inc | 8.90% | |
---|---|---|
Arcellx Inc | 6.68% | |
4D Molecular Therapeutics Inc Ordinary Shares | 4.44% | |
Iovance Biotherapeutics Inc | 3.63% | |
Rocket Pharmaceuticals Inc | 3.42% | |
Silence Therapeutics PLC ADR | 3.36% | |
Stoke Therapeutics Inc | 3.21% | |
Sarepta Therapeutics Inc | 2.86% | |
Voyager Therapeutics Inc | 2.65% | |
Q32 Bio Inc | 2.54% | |
Last data update | 30.04.2024 |
TER | |
---|---|
TER date | |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.60% |
Ongoing Charges *** | 1.03% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |